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ABSTRACT OF RESEARCH 
 
BACKGROUND: Recently, South African health system has been experiencing 
shortage of blood and blood products due to increase in demand for conditions 
(such as road accident injuries, assaults, surgery and complications of labour) 
and decrease in supply due to conditions such as Human Immunodeficiency 
Virus and Hepatitis B. This resulted in difficulty in managing conditions such as 
obstetric haemorrhages which is one of the commonest causes of maternal 
mortality and morbidity in South Africa. It was therefore important to monitor the 
use of these products in South African hospitals to avoid inappropriate use as 
well as to contain expenditure. However, no formal study has been done in 
recent past to systematically study the use of blood and blood products in the 
maternity units in these hospitals. The researcher believed that this study that 
was conducted in the Boitumelo Regional Hospital based in the Free State would 
provide evidence to provincial as well as institutional managers regarding the use 
of blood and blood products and to quantify financial resources spent on these 
items. This particular Hospital was chosen because of its significant expenditure 
on the blood and blood products mainly for maternity patients.  
 AIM: To determine the extent of the use of blood and blood products in the 
Maternity ward of the Boitumelo Regional Hospital and the factors that influenced 
their uses.  
METHODOLOGY: The study design was a cross-sectional study based on 
retrospective review of routinely collected hospital data from hospital records of 
patients for the period of 1 April 2009 to 31 March 2010. The setting of the study 
was the maternity ward of Boitumelo Regional Hospital. Data was collected on 
the following variables: types of blood and blood products transfused, profile of 
patients transfused with blood and blood products, turn-around time and cost of 
these products. Data from the hospital records was captured in the data 
collection tools designed for the study and descriptive statistics was used to 
report the findings.  
vi 
 
RESULT: This is probably the first study done at a regional hospital setting in 
South Africa which looked at broad issues pertaining to the use of blood and 
blood products in the Maternity ward of the Boitumelo Regional Hospital, and the 
factors associated with these specified blood and blood products during one 
study period. The study found 99 (4.2%) among these 2304 patients delivered 
during this one year period received blood and blood products transfusion (13 
units of whole blood, 250 units of red blood cells,  33 units of fresh frozen plasma 
and 1 unit of platelet). Primiparity (32, 32.6%), pre-term labour (49, 49.5%), 
booking status (unbooked 20, 20.4%) were found to be common among these 
patients. A significant number of them (36, 36.4%) were anaemic based on their 
booking haemoglobin but only a few of them were diagnosed and treated for 
anaemia. Among the other antenatal diseases, Pregnancy Induced Hypertension 
was commonest (27.3%) followed by Human Immunodeficiency Virus (15.2%). 
The majority of the subjects who received transfusion had Normal Vaginal 
Delivery signifying the need for active management of third stage.  Only 5% 
(36/776) of Caesarean Section patients received transfusion, which is much 
lower than other studies. The median blood loss during delivery was 400 ml. 
Seventeen (17.5%) patients were transfused before delivery and one (1%) was 
transfused during delivery and 81 patients (81.5%) were transfused after 
delivery. Eighteen of them (18.4%) were transfused for Antepartum 
Haemorrhage and 81 (81.6%) of them were transfused for Postpartum 
Haemorrhage. The median time interval between prescription and administration 
was 160 min which is quite long and could be improved by reducing the interval 
between prescription and ordering blood and interval between receipt and 
administration. The total cost of transfusion during one year study period was R 
329,579.27 (Whole blood: R7, 433.37, Red Blood Cell: R282, 192.50, Fresh 
Frozen Plasma: R33, 411.37 and Platelet: R6, 542.03) and the average cost of 
transfusion per patient was R3329.01.  
CONCLUSION: The findings of this study will be reported to the Hospital 
management for improving management of obstetrics patients. The researcher 
also proposed further study among all the patients who received transfusion at all 
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the regional hospitals in the Free State Province to compare the use of blood and 
blood products in these institutions. 
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GLOSSARY OF TERMS 
 
Antepartum Haemorrhage – is defined as bleeding from the genital tract in late 
pregnancy, after the 28th week of gestation and before the onset of labour 
(Bennett and Brown 1989) 
 
Blood Expanders – are defined as resuscitation fluids used in acute clinical 
conditions associated with hypovolemia (Department of Health, 2008 - Clinical 
Guidelines for the use of Blood and Blood Products in South Africa). 
 
Confidential Enquiries into Maternal Deaths – is defined as a systematic 
multidisciplinary anonymous investigation of all or a representative sample of 
maternal deaths occurring at an area, region (state) or national level which 
identifies the numbers, causes and avoidable or remedial factors associated with 
them (Pattison, Makin and Delport 1995). 
 
Ectopic pregnancy – it is defined as a condition whereby a fertilized ovum 
embeds outside the uterus (Bennett and Brown 1989) 
 
Fresh Frozen Plasma – is plasma separated from anticoagulated whole blood 
within 18 hours of donation and it is done by centrifuging whole blood in a closed 
sterile system and freezing the plasma to below -18 degree Celsius (Department 
of Health, 2008 - Clinical Guidelines for the use of Blood and Blood Products in 
South Africa). 
 
Maternal Death Rate – refers to the number of maternal deaths in a given time 
period per 100 000 women of reproductive age during the same period 
(Beksinska, Kunene and Mullick 2004)  
 
Maternal Mortality – it is defined as the death of a woman while pregnant or 
within 42 days of termination of pregnancy, from any cause related to or 
xiv 
 
aggravated by the pregnancy or its management, but not from accidental causes 
(The International Classification of Diseases, Injuries and Causes of Death – 10th 
Revision). 
 
Maternal Mortality Ratio – it is defined as the number of women who die as a 
result of childbearing, during the pregnancy or within 42 days of delivery or 
termination of pregnancy in one year, per 100 000 live births during that year 
(Beksinska, Kunene and Mullick 2004). 
 
Postpartum Haemorrhage – is defined as excessive bleeding from genital tract 
after delivery (Department of Health 2007. Saving Mothers - Essential Steps in 
the Management of Common Conditions Associated with Maternal Mortality).  
 
Whole Blood – is defined as a complex tissue from which the numerous and 
clinically appropriate components are processed and it is used in massive 
haemorrhage with possibility of recurrence or continuation (Department of 
Health, 2008 - Clinical Guidelines for the use of Blood and Blood Products in 
South Africa). 
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AIDS Acquired Immunodeficiency Virus 
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APH Antepartum Haemorrhage  
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CCF Congestive Cardiac Failure 
CS Caesarean section 
FFP Fresh Frozen Plasma 
GA Gestational Age 
Hb Haemoglobin 
Hct Haematocrit 
HIV Human Immunodeficiency Virus 
HST Health Systems Trust 
MDG Millennium Development Goals  
MMR Maternal Mortality Ratio 
NVD Normal Vaginal Delivery 
Plt Platelet 
PPH Postpartum Haemorrhage 
RBC Red Blood Cells 
SADHS South African Demographic and Health Survey 
StatsSA Statistics South Africa 
WHO World Health Organization 
 
 
1 
 
CHAPTER 1 
INTRODUCTION 
 
The purpose of this study was to determine the extent of the use of blood and 
blood products in the Maternity ward of a Regional Hospital and the factors that 
influence their uses.  This introductory chapter will cover the background to the 
study, statement of the problem, its aims and objectives and an outline of 
subsequent chapters. 
 
1.1 BACKGROUND 
 
Transfusion of blood and blood products is a requirement to save patients lives 
thus the need for the hospital to ensure availability of these items at all times. 
They form an integral and essential part in the management of obstetric patients. 
Blood transfusions involve a number of factors including availability, the 
indications for transfusion, the process itself, as well as the complications that 
may arise from the transfusion (Basu, Hartford, Nzama, et al, 2012).  
 
Hospitals in the public sector have a dedicated budget for blood and blood 
products. Clinicians are expected to follow blood and blood products transfusion 
policies and guidelines when they prescribe these products to ensure optimum 
use of allocated resources. Those who are charged with the responsibility of 
ensuring that blood and blood products are transfused to patients must ensure 
that these items are not wasted at all times. 
 
1.2 JUSTIFICATION OF STUDY  
 
Recently, South African health system has been experiencing shortage of blood 
and blood products due to increase in demand for conditions (such as road 
accident injuries, assaults, surgery and complications of labour) and decrease in 
supply due to conditions such as HIV and Hepatitis B. This resulted in difficulty in 
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managing conditions such as obstetric haemorrhages which is one of the 
commonest causes of maternal mortality and morbidity in South Africa. It is 
therefore important to monitor the use of these products in South African 
hospitals to avoid inappropriate use as well as to contain expenditure. However, 
no formal study has been done in recent past to systematically study the use of 
blood and blood products in the maternity units in these hospitals. The 
researcher believes that this study will be able to address that gap and will be 
able to provide evidence to institutional as well as provincial management 
regarding appropriate use of blood and blood products and to quantify financial 
resources spent for these items.  
 
1.3 MOTIVATION FOR THE STUDY  
 
Boitumelo Regional Hospital is a 312 bed hospital, situated in the Fezile Dabi 
District (previously known as the Northern Free State District) in the Free State 
Province. The Hospital experiences between 180 – 250 normal deliveries per 
month and between 65 – 74 complicated deliveries per month. Over the past few 
years the Hospital has been overspending on blood and blood products and the 
majority of the blood products are being used in the Maternity ward. Therefore, it 
is felt that there is a need to systematically study the use of blood and blood 
products in the Maternity unit to optimise their use.  
 
1.4 RESEARCH QUESTION 
 
What is the use of blood and blood products in the Maternity ward of the 
Boitumelo Regional Hospital? What factors influence their use? What is the turn-
around time and what is their cost? 
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1.5 STUDY OBJECTIVES 
 
1.5.1 BROAD OBJECTIVE  
 
To describe the use of blood and blood products in the Maternity ward of the 
Boitumelo Regional Hospital, the factors associated with these specified blood 
and blood products during the study period of 1 April 2009 to 31 March 2010. 
 
1.5.2 SPECIFIC OBJECTIVES 
 
I. To describe the specified blood and blood products ordered in this 
ward during the study period. 
 
II. To determine the number of patients who received transfusion during 
the study period. 
 
III. To determine the factors (such as demographic profile, obstetric 
profile, transfusion, and maternal and foetal outcome) associated with 
utilization of these products in the maternity ward during the study 
period.  
 
IV. To determine the turn-around time of these products. 
 
V. To determine cost of these products used during the study period. 
 
1.6 SUBSEQUENT CHAPTERS 
 
So far, the background to the research has been discussed. Then, research 
question and objectives were defined in this first chapter. A brief outline of the 
4 
 
following chapters is described below.  
 
Chapter Two: Literature Review: The purpose of the literature review is to 
review pertinent literature and to discuss concepts related to the use of blood and 
blood products in the Maternity ward in hospitals in South Africa and elsewhere.  
 
Chapter Three: Research Methodology: The chapter describes the research 
methodology, study design, setting and scope and data management techniques 
used in this study. 
 
Chapter Four: Presentation of Results: This chapter deals with an analysis of 
the data collected for this study relating to its aims and objectives. 
 
Chapter Five: Discussion: The findings from the review of the literature are 
incorporated in this chapter with the results obtained from the analysis in order to 
address the aims and objectives of the study. 
 
Chapter Six: Conclusions and Recommendations: This constitutes the last 
chapter of the report and derives conclusions from the research related to the 
objectives of this study, makes recommendations and advocates areas for future 
research in the field of the transfusion of blood and blood products in the 
maternity ward.  
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CHAPTER 2 
LITERATURE REVIEW 
 
In this chapter, relevant literatures into the field of the transfusion of blood and 
blood products in the maternity ward are discussed. In addition to published 
literature, information from various unpublished sources is also reviewed.  
 
2.1 MATERNAL HEALTH SERVICES 
 
Millennium Development Goal number 5 stipulates that maternal mortality rate 
must be reduced by three-quarters (75%) between 1990 and 2015 (WHO, 2004). 
The countries in Sub-Saharan Africa have the biggest challenge to achieve these 
goals as the child and maternal death rates are highest in this region (WHO, 
2005).  
 
South Africa is one of the countries that have prioritised the lives of both mothers 
and children to achieve the targets of MDG 5 (Department of Health. 2007e).  
 
Although free maternal care was introduced for all South Africans in 1995, 
Maternal Mortality Ratio remained significantly high (400/100 000 in 2005) for a 
middle-income country such as South Africa (Hill, Thomas, AbouZahr, et al. 
2007; HST, 2010). 
 
 In 1998, the South African Demographic and Health Survey (SADHS) reported a 
Maternal Mortality Ratio (MMR) of 150 per 100 000 live births, while in 2002, 
Statistics South Africa (StatsSA) estimated MMR to be at 124/100 000. During 
the period of 2005–2007; there has been a 20.1% increase in the number of 
deaths. Obstetric haemorrhage (antepartum and postpartum haemorrhage; 
12.4%) remained as one of the big five causes of maternal mortality in South 
Africa, other conditions being non-pregnancy related infections – mainly AIDS 
(43.7%), complications of hypertension (15.7), pregnancy-related sepsis (9.0%), 
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and pre-existing maternal disease (6.0%). The risk of death from obstetric 
haemorrhage is highest among the women 35 years and older.  Complications of 
obstetric haemorrhage among others were responsible for 4 out of 5 of the 
avoidable deaths (Department of Health, 2007a; Department of Health, 2007b; 
Department of Health, 2007c). In view of that, the Committee on Confidential 
Enquiries into Maternal Deaths in South Africa suggested availability of blood 
and blood products for transfusion (whole blood, fresh frozen plasma, platelets 
and blood expander) as one of their key recommendations for improvement of 
maternal health services in South Africa.  
 
Recommendations included the following; Improving health care provider 
knowledge and skills in providing emergency care and ensuring adequate 
screening and treatment of the major causes of maternal death and improving 
quality and coverage of reproductive health services, namely; contraceptive and 
termination of pregnancy services. The recommendations also included 
management and provision of staffing and equipment norms, transport as well as 
community involvement and empowerment regarding maternal, neonatal and 
reproductive health in general (Department of Health, 2007c).  
 
2.2 OBSTETRIC HAEMORRHAGES  
 
Obstetric haemorrhage is one of the leading causes of maternal mortality and 
morbidity (WHO, 2005). Obstetric haemorrhage accounts for 34% of maternal 
deaths in Africa (Khan, Wojdyla, Say, et al., 2006; Bates, Chapotera, McKew, et 
al., 2008). About half of the global maternal deaths from severe bleeding occurs 
in sub-Saharan Africa (Ronsmans and Graham, 2006; Bates et al, 2008). In a 
study by Gandhi et al (2004) undertaken in Kwa-zulu Natal, South Africa, it was 
found that haemorrhage accounts for 32% of cases of severe acute maternal 
morbidity. This study also took note that 57% of maternal mortality cases at a 
tertiary hospital in Pretoria were referred from primary care where a scarcity of 
blood products led to insufficient management (Gandhi, Welz, and Ronsmans, 
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2004). Furthermore, the National Department of Health recorded that Obstetric 
Haemorrhage (both antepartum and postpartum haemorrhage) accounted for 
13.4% of direct causes of maternal deaths during the year 2002-2004 
(Department of Health, 2007c). 
 
Obstetric haemorrhages can be broadly classified as early pregnancy (such as 
ectopic pregnancy and abortion), antepartum (such as placenta preavia and 
placenta abruption), intrapartum and postpartum (Jansen, van Rhenen, 
Steegers, et al., 2005). Blood transfusions form an integral and essential part in 
the management of patients with obstetric haemorrhage. Timely and appropriate 
intervention can make the greatest difference to a possibly disastrous outcome 
from a patient with obstetric haemorrhage (Jansen et al, 2005). 
 
Blood transfusions involve a number of factors including available blood 
products, the indications for transfusion, the process itself, as well as the 
complications that can arise from the transfusion.  
• The majority of transfusions are required following post-partum 
haemorrhage and 96% of blood transfusions are performed in the 
postpartum period. The remaining 4% are performed antenatally (Parker, 
Thompson and Stanworth, 2009).  
• The common antepartum indications for blood transfusion include ectopic 
pregnancy, abortion, disorders of placentation (including accreta, placenta 
previae), abruptio placenta, multiple pregnancy, oligohydramnios, 
polyhydramnios and previous history of abortions and antepartum 
haemorrhage (Nel, 1995).  
• During intra-partum period, blood transfusions were found to be 
associated with preterm pregnancy, low birth weight of infant, short 
duration of labour and longer duration of ruptured membranes, caesarean 
section (CS), Induction of labour, assisted delivery and in breech 
extraction (Nel, 1995). Whereas, CS is the main trigger factor for blood 
transfusion during delivery (Ozumba and Ezegwui, 2006), the patients 
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who had induction of labour with oxytocin were 2.3 times more likely to 
require transfusion (Klapholz, 1990). A Nigerian study reported the rate of 
transfusion to be 25% among the CS patients which was related strongly 
to indications for C/S, preoperative anaemia and blood loss at CS. 
(Ozumba and Ezegwui, 2006)  
 
It was suggested that women in the high-risk categories should be warned of the 
possibility of transfusion so that autologous donation can be considered 
especially in light of the fact that 84% of the transfused patients required 3 or less 
units (Klapholz, 1990). 
 
The amount of blood and blood products used in obstetric patients varies and 
depends on multiple factors, such as baseline Haemoglobin (Hb), Hematocrit 
(Hct), Platelet, amount of blood loss, obstetric condition. A study done in the USA 
found that 2.6% of the patients required transfusion and the amount of 
transfusion varied (1U: 11.2%, 2U: 61% and 8U or more: 4%) (Klapholz, 1990).  
 
 
2.3 USE OF BLOOD AND BLOOD PRODUCTS 
 
The common blood and blood products being transfused in our maternity ward 
include; Red Cell components, platelets, plasma components and derivatives. 
Each of these products has specific indications for transfusion. For example, 
indication for red blood cell transfusion is the restoration of oxygen-carrying 
capacity. Whole blood or red cell concentrates are used to improve tissue 
oxygenation when this is impaired by haemorrhage or anaemia. An acute blood 
loss of greater than 20% of blood volume (about 1000-1200 ml of blood in an 
adult) will often result in the need for red cell transfusion (Department of Health, 
2008).  
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However, in many instances correct indications are not always followed. For 
example, a study conducted in a rural district hospital in western Kenya between 
September 1990 and July 1991 revealed that 47% of paediatric transfusions 
were classified as inappropriate; 23% did not meet the criteria of having 
haemoglobin < 5.0 g/dl and 27% were transfused two or more days after having 
been requested. It was concluded that improved laboratory services, reduction of 
unnecessary transfusions, and increased recruitment of volunteer donors are 
critical for improving the appropriate and timely use of blood and reducing 
transfusion-associated HIV transmission (Ifenne, Essien, Golji, et al., 1997). 
 
The study conducted in the maternity units of eight hospitals in three districts in 
Malawi revealed that Malawi Blood Transfusion Service provided 66.7% of the 
blood used by hospitals while the decentralised hospital-based system provided 
the rest of one-third. The major challenges faced by the dual system included 
poor communication, inadequate knowledge of the availability and clinical use of 
blood, difficulties recruiting and retaining donors, difficulties distributing blood, 
high prevalence of HIV and costs of running the two systems.  
 
In South Africa, the use of blood and blood products is regulated and legislated 
by the National Health Act, 2004 (South Africa, 2004).  
 
Although blood transfusion is a necessary and often life-saving intervention, it is 
also associated with a number of serious complications. Santoso, Lin, Miller, 
(1995) described the complications of transfusion in three categories according 
to aetiology: infectious, non-infectious and immunological. There is a lack of 
research regarding the rates of transfusion related complications in obstetric 
practice in South Africa.  
 
2.4 COST OF BLOOD AND BLOOD PRODUCTS 
 
Transfusion support is an essential component of clinical medicine, with 
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transfusion being life-saving in many acute situations and many chronically ill 
individuals receiving regular therapy (Guidelines for National Blood Transfusion 
Services 2006). Poor public and donor awareness, loss of staff working in blood 
transfusion services and the changes in the clinical demand for blood and blood 
products, lead to high demands for the service resulting in high costs of such 
blood and blood products. Activities such as; blood donor recruitment, blood 
collection, blood processing and blood storage and distribution together with 
capital and recurrent costs play a major role in determining the cost.   
 
South African National Blood Service determines pricing scales regarding; 
clinical services, diagnostic state prices, blood and platelet products and 
pathology services prices. These prices are provided per individual product and 
are invoiced as per request. It is therefore possible to cost each and every unit or 
item ordered. They also provide tariffs for after-hours service that they have 
provided.    
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CHAPTER 3 
METHODOLOGY 
 
The methodology for this study was selected on the basis of its aims and 
objectives. In this chapter the following were discussed: setting, scope, and study 
design and research tools. 
 
3.1 STUDY DESIGN 
 
A cross sectional study design was used for this study. Retrospective record 
review was done and information was extracted from data contained in the 
Boitumelo Regional hospital maternity registers, laboratory registers, blood and 
blood products administration register for the period 01 April 2009 – 31 March 
2010.  
 
3.2 SETTING OF THE STUDY   
 
The setting of this study is the Maternity ward at Boitumelo Regional Hospital.  
 
Boitumelo Regional Hospital is situated in the Fezile Dabi District (previously 
known as the Northern Free State District) in the Free State Province. The 
District comprises of four sub-districts, namely; Moqhaka (wherein Boitumelo 
Regional Hospital is situated), Metsimaholo (wherein Metsimaholo District 
Hospital is situated), Ngwathe (wherein both Parys and Tokollo District Hospitals 
are situated) and Mafube (wherein Mafube District Hospital is situated). These 
four district hospitals refer their patients (including complicated maternity cases) 
to Boitumelo Regional Hospital.  
 
Boitumelo Regional Hospital is the only Level 2 hospital in the district and the 
only hospital in the Moqhaka sub-district. As a result of that, it has to provide 
some Level 1 services to patients that are supposed to be managed at district 
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hospitals. There are two community health centres and eight primary health care 
clinics within Moqhaka Sub-district.  These two community health centres refer all 
their complicated maternity cases to Boitumelo Regional Hospital. The District 
has a population of about 518,024 of which 441,580 (85%) is uninsured (Free 
State Department of Health, 2008). 
 
 
Figure 3.1 Fezile Dabi District 
 
Although the Hospital has 345 approved beds, only 312 beds are currently used.  
In the Maternity unit, there are 13 antenatal beds, 7 labour (delivery) beds, 22 
post natal beds and 11 lodger and kangaroo beds. Average bed occupancy rate 
of the Unit is approximately 95% through-out the year. The Hospital experiences 
between 180 – 250 normal deliveries per month and between 65 – 74 
complicated deliveries per month.  
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3.3 SCOPE OF THE STUDY 
 
The study involved retrospective review of patients’ records who delivered at the 
Maternity Unit of the Boitumelo Hospital and received transfusion. No primary 
data was collected for the study. No intervention was done.  
 
3.4 STUDY PERIOD  
 
The study period was one year from 01 April 2009 to 31 March 2010.  
 
3.5 STUDY POPULATION AND SAMPLE 
 
The study population included the maternity patients who had received 
transfusion of blood and blood products at the Boitumelo Regional Hospital 
during the study period. 
 
All the patients who fulfilled the above criteria were included. Therefore, no 
sampling was done. 
 
3.6 VARIABLES 
 
Data was collected on various variables as listed in Table 3.1. 
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Table 3.1 Relevant objectives and study variables 
Objective    Variables Type 
I Units of blood 
and blood 
product used  
• Units of blood and blood product used 
per type  
Numerical 
II Patients who 
received 
transfusion 
 
• Number of patients received transfusion 
• Proportion of inpatients received 
transfusion 
Numerical 
Numerical 
III Demographic 
profile 
• Age (years) 
• Ethnicity 
• Hospital classification 
Numerical 
Categorical 
Categorical 
 Antepartum 
profile 
• Parity 
• Gestational age(weeks) 
• Number of visits 
• Booking blood results (Hb) 
• Antepartum diseases 
• Number of Antepartum admissions  
Categorical 
Numerical 
Categorical 
Numerical 
Categorical 
Categorical 
 Intrapartum 
profile 
• Mode of delivery  
• Blood loss (ml) 
• Blood results (Hb, Haematocrit and 
Platelet) on admission 
• Intrapartum diseases  
Numerical 
Numerical 
Categorical 
 
Categorical 
 Postpartum 
profile 
• Complications (such as postpartum 
haemorrhage)  
• Time of presentation/occurrence 
(immediate or remote postpartum).  
Categorical 
 
Categorical 
 Transfusion 
profile 
• Times prescribed, ordered and 
administered 
•  Pregnancy status at time of transfusion 
(antepartum, intrapartum & postpartum) 
• Haemoglobin level (immediately pre and 
post transfusion) 
• Platelet level (immediately pre and post 
transfusion) 
• Indication(s) for transfusion   
• Quantity of units transfused per type  
• Quantity rejected 
• Reason(s) for rejection 
Numerical 
 
Categorical 
 
Numerical 
 
Numerical 
 
Categorical 
Numerical 
Numerical 
Categorical 
 
 Maternal & 
foetal 
outcome 
• Discharged, transferred, died Categorical 
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3.7 DATA COLLECTION 
 
Permission to conduct the study was sought from the Chief Executive Officer of 
the Hospital. Data for this study was routinely collected on monthly basis as part 
of Hospital Information System. Data from various sources within the Maternity 
ward was exported to MS Excel and then extracted to MS Excel based data 
collection tools designed for this study (Annexure A). Study numbers were 
allocated to each patient to maintain confidentiality. 
 
3.8 DATA ANALYSIS  
 
Extracted data was analysed with NCSS (NCSS, 2007). Descriptive data 
analysis was used such as central tendency (mean and median) and spread 
(standard deviation and interquartile range) for numerical variables. Categorical 
variables (such as ethnicity) were presented as proportions. Analytical statistics 
(such as t-test or Mann-Whitney’s U test (if data is not normally distributed) for 
numerical variables and chi-square test for categorical variables) was used to 
compare between two groups (such as Hb level before and after transfusion). 
 
3.9 ETHICAL CONSIDERATIONS 
 
Information was collected anonymously from the patients’ records, maternity 
registers and blood bank records; using the data tool developed for each 
objective. No patient names or hospital numbers was used; rather study numbers 
were allocated to different patients. Raw data from where the information was 
extracted was only available to the researcher. Permission to conduct the 
research at Boitumelo Regional Hospital was sought from the Chief Executive 
Officer of the Hospital. The researcher also received approval from the Human 
Research Ethics Committee (Medical) of the University of the Witwatersrand.  
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CHAPTER 4 
RESULTS 
 
The results obtained from the analysis of data were described in this chapter. 
 
4.1 NUMBER OF DELIVERIES 
 
The number of deliveries during the study period is listed in the Table 4.1. The 
majority of patients had normal delivery (1474, 64%). Thirty-four percent (n=776) 
women had caesarean section and 2% (n=54) had assisted vaginal delivery.  
 
Table 4.1 Number of deliveries  
 Total deliveries NVD CS Assisted 
deliveries 
April 2009 200 138 57 5 
May 2009 177 118 59 0 
June 2009 225 145 67 13 
July 2009 193 131 57 5 
August 2009 192 118 70 4 
September 2009 199 131 59 9 
October 2009 167 109 56 2 
November 2009 174 99 72 3 
December 2009 205 138 65 2 
January 2010 175 100 72 3 
February 2010 162 104 57 1 
March 2010 235 143 85 7 
Total  2304 1474 776 54 
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Figure 4.1 Number of deliveries 
 
4.2 NUMBER OF PATIENTS WHO RECEIVED TRANSFUSION 
 
The number of deliveries during the study period is listed in the Table 4.2. Ninety-
nine (4.2%) among these 2304 patients received blood and blood products 
transfusion. 
 
Table 4.2 Number of patients receiving transfusion 
 Total deliveries No received transfusion 
April 2009 200 13 (14%) 
May 2009 177 8 (8%) 
June 2009 225 5 (5%) 
July 2009 193 8 (8%) 
August 2009 192 12 (12%) 
September 2009 199 11 (11%) 
October 2009 167 9 (9%) 
November 2009 174 6 (6%) 
December 2009 205 5 (5%) 
January 2010 175 5 (5%) 
February 2010 162 10 (10%) 
March 2010 235 7 (7%) 
Total  2304 99 (4.2%) 
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The following sections will describe the profiles of patients who received 
transfusion.  
 
4.3 SOCIO-DEMOGRAPHIC PROFILE 
 
4.3.1 AGE 
 
The mean age of the subjects was 26 years (+ 6.7 years). The minimum and 
maximum ages were 16 and 42 years. 
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Figure 4.1 Age distribution 
 
4.3.2 ETHNICITY 
 
The ethnicity of the subjects is described in Table 4.3 
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Table 4.3 Ethnicity of the subjects 
Ethnicity Count (%) 
Coloured 1 (1.01%) 
Sotho 59 (59.6%) 
Xhosa 25 (25.25%) 
Zulu 14 (14.14%) 
Total  99 (100%) 
 
4.3.3 HOSPITAL CLASSIFICATION 
 
All patients were classified as non-paying (H0) patient.  
 
4.4 OBSTETRIC PROFILE 
 
4.4.1 PARITY 
 
The parity of the subject is described in Table 4.4. The median parity was 1 
(Inter-quartile range was 0 to 2).  
 
Table 4.4 Parity 
Parity Count Percentage 
0 32 32.65 
1 28 28.57 
2 23 23.47 
3 10 10.2 
4 4 4.08 
5 1 1.02 
Total 99 100 
 
 
4.4.2 GESTATIONAL AGE AT THE TIME OF DELIVERY 
 
The mean age was 35 weeks (+ 4.1 years). The minimum and maximum 
gestational ages were 23 and 40 (Figure 4.2).  
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Figure 4.2 Gestational age at the time of delivery 
 
 
4.4.3 NUMBER OF ANC VISITS 
 
The median number of ANC visits was 2 (Inter-quartile range was 1 to 4) (Figure 
4.3).  
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Figure 4.3 Number of ANC visits  
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4.4.4 BOOKING BLOOD RESULTS 
 
The mean haemoglobin at the time of booking was 10.6 g/dl (+ 1.7 g/dl) with 
minimum and maximum levels were 6.7 and 14 g/ dl (Figure 4.4). Thirty-six 
(36%) of them had anaemia according to booking blood result (Hb < 11 g/ dl).  
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Figure 4.4 Booking Hb (g/dl)  
 
 
4.4.5 DISEASES DURING ANTENATAL PERIOD 
 
Fourty-three (43%) subjects had some diseases during antenatal period (Table 
4.5). Some patients had more than one disease. Pregnancy Induced 
hypertension was commonest (27.3%), followed by HIV (15.2%). Anaemia was 
detected in only 10 (10.1%) of subjects, although 36% (36%) of them had 
anaemia according to booking blood result (Hb < 11 g/ dl). 
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Table 4.5 Diseases during antenatal period 
Diseases Count Percentage 
Anaemia 10 10.1% 
CCF 1 1.0% 
Pregnancy Induced Hypertension 27 27.3% 
Asthma 1 1.0% 
HIV  15 15.2% 
 
Six of them required admission during ante-natal period. Two of the patients with 
Pregnancy Induced Hypertension developed HELLP Syndrome.  
 
Obstetrics problems found during the antenatal period were listed in Table 4.6.  
 
Table 4.6 Obstetric diseases during antenatal period 
Diseases Count Percentage 
Antepartum Haemorrhage (APH) 18 18.4% 
Pre-term labour 49 49.5% 
Oligohydramnios 1 1.0% 
 
 
4.4.6 MODE OF DELIVERY 
 
The mode of delivery of the subject was described in Table 4.7. The percentage 
of NVD is slightly lower than the entire cohort of patients who delivered at the 
hospital during this period.   
 
Table 4.7 Mode of delivery 
Mode of delivery Count Percentage 
Normal Vaginal Delivery 59 59.6% 
Born Before Arrival 1 1.0% 
Breech 2 2.0% 
Caesarean Section 36 36.4% 
Twin  1 1.0% 
Total 99 100.0% 
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4.4.7 TOTAL BLOOD LOSS 
 
The total blood loss during this period is described in Figure 4.5. The median 
blood loss was 400 ml (Inter-quartile range was 300 ml to 500 ml).  The minimum 
and maximum blood losses were 100 ml and 1500 ml respectively. Among the 
patient who had vaginal delivery (n=63), 17 (27%) had blood loss more than 500 
ml. Among the patient who had CS (n=36), one (3%) subject had a blood loss 
more than 1000ml.  
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Figure 4.5 Total blood loss (ml)  
 
 
4.4.8 BLOOD RESULTS 
 
The pre-transfusion Hb result is described in Figure 4.6. The median Hb was 6.9 
g/dl (Interquartile range 6.1 g/dl to 7.6 g/dl). The minimum and maximum Hb 
were 1.9 g/dl and 9.9 g/dl respectively. All of them had a Hb less than 11 g/ dl.  
 
24 
 
0.0
10.0
20.0
30.0
40.0
0.0 2.5 5.0 7.5 10.0
C
o
u
n
t
 
 
Figure 4.6 Pre-transfusion Hb (g/dl)  
 
The pre-transfusion Hct result is described in Figure 4.7. The median Hct was 
0.23 (Interquartile range 0.18 to 0.26). The minimum and maximum Hct were 0.1 
and 0.35 respectively.  
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Figure 4.7 Pre-transfusion Hct  
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The pre-transfusion platelet result is described in Figure 4.8. The median platelet 
level was 242,000/µl (Interquartile range 154,000/ µl to 313,000/ µl). The 
minimum and maximum platelet levels were 45,000/ µl and 507,000/ µl 
respectively.  
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Figure 4.8 Pre-transfusion Platelet level (in 000/ µl) 
 
 
4.5 TRANSFUSION 
 
4.5.1 INDICATIONS FOR TRANSFUSION 
 
Seventeen (17.5%) patients were transfused before delivery and one (1%) was 
transfused during delivery and 81 patients (81.5%) were transfused after 
delivery. 
 
Eighteen of them (18.4%) were transfused for APH and 81 (81.6%) of them were 
transfused for PPH.  
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4.5.2 BLOOD RESULTS BEFORE AND AFTER TRANSFUSION 
 
The median Hb level after transfusion was 9.8 g/ dl (Inter-quartile range 8.9 g/ dl 
to 10.5 g/ dl). The minimum and maximum Hb levels were 7.3 g / dl and 13.4 g/ 
dl respectively. There was a significant increase in Hb level between before and 
after transfusion (Mann-Whitney’s U test, p <0.0001).  
 
The median Hct level after transfusion was 0.31 (Inter-quartile range 0.23 to 
0.32). The minimum and maximum Hct levels were 0.15 and 0.37 respectively. 
There was a significant increase in Hct level between before and after 
transfusion (Mann-Whitney’s U test, p <0.01).  
 
The median platelet level after transfusion was 211,000/ µl (Inter-quartile range 
144,000/ µl to 308,00/ µl). The minimum and maximum platelet levels were 
59,000/ µl and 359,000/ µl respectively. There was no significant increase in 
platelet level between before and after transfusion (Mann-Whitney’s U test, p 
=0.1).  
 
4.5.3 TRANSFUSION PRODUCTS 
 
There were four types of transfusion products used: Whole Blood, Red Blood 
Cells, Fresh Frozen Plasma and Platelets. The number of units used for each 
type of products is listed in Table 4.8.  
 
Table 4.8 Transfusion products 
 Number of patients Total units Average per patient 
Whole Blood 3 13 4.3 
Red Blood Cells 99 250 2.5 
Fresh Frozen 
Plasma 
11 33 3 
Platelets 1 1 1 
 
 
27 
 
Monthly uses of these products are shown in Figure 4.9. There are some 
variations in monthly uses, but they are not statistically significant (p=0.1).  
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Figure 4.9 Monthly uses of transfusion products 
 
 
4.5.4 REJECTION OF TRANSFUSION UNITS  
 
All patients who were legible to receive blood and or blood products received 
their units. None of the units were rejected. 
 
4.5.5 TURN-AROUND TIME  
 
The turn-around times for transfusion products are listed in Table 4.9. The 
median time interval between prescription and ordering blood was 30 min, 
whereas median time interval between order and receipt was 50 min and median 
time interval between receipt and administration was 60 min. The median time 
interval between prescription and administration was 160 min which is quite long, 
in an emergency situation like antepartum or post-partum haemorrhage.   
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Table 4.9 Turn-around time 
 Time between 
prescribed 
and ordered 
Time between 
ordered and 
received 
Time between 
received and 
administered 
Total time between 
prescribed and 
administered 
Median 30 min 50 min 60  min 160  min 
Inter-
quartile 
range 
15 min to  
70 min 
30 min to  
80  min 
45 min to  
65 min 
115 min to  
225 min 
Minimum 0 min 0 min 10 min 0  min 
Maximum 240 min 420 min 680 min 720  min 
 
 
4.6 COST OF TRANSFUSION 
 
The number of units used for four types of product (Namely whole blood, Red 
Blood Cells, Fresh Frozen Plasma and Platelet), their unit costs and total cost 
per month are listed in the Table 4.10. Thirteen (13) units of whole blood were 
transfused; two hundred and fifty (250) units of red blood cells were transfused 
and thirty three (33) units of fresh frozen plasma units were transfused while only 
one (1) unit of platelet was transfused. 
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Table 4.10 Cost of transfusion 
Month 
Unit Cost Number used Total Cost 
Whole 
Blood RBC Plasma Platelet 
Whole 
Blood RBC Plasma Platelet 
Whole 
Blood RBC Plasma Platelet 
April  
2009  R353.97  R1128.77  R903.01  R6542.03 0 33 3 0 R353.97 R37249.41 R2709.03 0 
May  
2009  R353.97  R1128.77  R903.01  R6542.03 2 18 0 0 R707.94 R20317.86 R903.01 0 
June  
2009  R353.97  R1128.77  R903.01  R6542.03 0 14 6 0 R353.97 R15802.78 R5418.06 0 
July 
 2009  R353.97  R1128.77  R903.01  R6542.03 0 25 0 0 R353.97 R28219.25 R903.01 0 
August  
2009  R353.97  R1128.77  R903.01  R6542.03 0 28 0 0 R353.97 R31605.56 R903.01 0 
Sept.  
2009  R353.97  R1128.77  R903.01  R6542.03 0 30 3 0 R353.97 R33863.10 R2709.03 0 
Oct. 
 2009  R353.97  R1128.77  R903.01  R6542.03 2 22 3 0 R707.94 R24832.94 R2709.03 0 
Nov.  
2009  R353.97  R1128.77  R903.01  R6542.03 0 15 6 0 R353.97 R16931.55 R5418.06 0 
Dec.  
2009  R353.97  R1128.77  R903.01  R6542.03 0 14 2 1 R353.97 R15802.78 R1806.02 R6542.03 
Jan.  
2010  R353.97  R1128.77  R903.01  R6542.03 0 14 7 0 R353.97 R15802.78 R6321.07 0 
Feb. 
 2010  R353.97  R1128.77  R903.01  R6542.03 6 22 0 0 R2123.82 R24832.94 R903.01 0 
Mar.  
2010  R353.97  R1128.77  R903.01  R6542.03 3 15 3 0 R1061.91 R16931.55 R2709.03 0 
Total 
    13 250 33 1 R 7,433.37 R 282,192.50 R 33,411.37 R 6,542.03 
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Whole blood units transfused for the research period cost the Hospital 
R7 433.37, Red Blood Cell R282 192.50, Fresh Frozen Plasma R33 411.37 while 
it cost the hospital R6 542.03 for the platelet transfusion (Figure 4.10). Patients 
requiring platelet transfusion are normally transferred to the tertiary hospital  
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Figure 4.10 Monthly cost of transfusion  
 
The total cost of transfusion during one year study period was R 329,579.27.  
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CHAPTER 5 
DISCUSSION 
 
In this chapter, the results obtained from the analysis of the data were discussed 
and compared with those from other published studies. 
 
5.1 INTRODUCTION 
 
This study was done in order to describe the use of blood and blood products in 
the Maternity ward of the Boitumelo Regional Hospital, the factors associated 
with these specified blood and blood products during one study period (1 April 
2009 to 31 March 2010). No study had been conducted at the level of a regional 
hospital in the Free State Province to look at the influence of various factors on 
the use of blood and blood products. 
 
Among the patients who delivered at the Boitumelo Regional Hospital (n=2304), 
99 (4.2 %) patients received blood and blood products transfusion, which was 
similar to the finding of the study done at the Charlotte Maxeke Johannesburg 
Academic Hospital (5%) (Basu, et al., 2012); however higher than a study done 
in the USA found 2.6% of the obstetrics patients required blood transfusion.  
 
5.2 PROFILE OF PATIENTS 
 
The mean age of the subjects was 26 years (+ 6.7 years). The majority of them 
were Sotho speaking (n=59, 59.6%), followed by Xhosa speaking 25 (25.2%). All 
patients were classified as non-paying (H0) patient, which implies that Hospital 
had to pay the entire cost incurred for blood transfusion.  
 
The median parity was 1. Almost third of them (32, 32.6%) were primipara.  The 
mean gestational age was 35 weeks (+ 4.1 years). The minimum and maximum 
gestational ages were 23 and 40. Fourty-nine (49.5%) of them had gestational 
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age less than 37 weeks, signifying a possible link between pre-term labour and 
need for blood transfusion.  The median number of ANC visits was 2 (Inter-
quartile range was 1 to 4). Twenty (20.4%) of them never attended any antenatal 
clinic.   
 
The mean haemoglobin level at the time of booking was 10.6 g/dl (+ 1.7 g/dl). 
Anaemia was diagnosed in only 10 (10.1%) of subjects, although 36 (36.4%) of 
them had anaemia according to booking blood result (Hb < 11 g/ dl). One of the 
anaemic patient subsequently developed Congestive Cardiac Failure. This 
signifies poor antenatal management of anaemia and failure to detect anaemia 
based on booking blood results and to provide iron and folic acid which could 
have avoided the need for blood transfusion. Among the other antenatal 
diseases, Pregnancy Induced hypertension was commonest (27.3%) followed by 
HIV (15.2%).  
 
Unlike other studies (Klapholz, 1990; Nel, 1995), the majority of the subjects who 
received transfusion, (59, 59.6%) had NVD, which was similar to the findings of 
the South African study which reported 61% had NVD (Basu, et al., 2012).  Only 
5% (36/776) CS patients received transfusion, which is much lower than the 
figure (25%) reported in the Nigerian study (Ozumba and Ezegwui, 2006). 
 
The median blood loss was 400 ml (Inter-quartile range was 300 ml to 500 ml).  
The minimum and maximum blood losses were 100 ml and 1500 ml respectively. 
Among the patients who had vaginal delivery (n=63), 17 (27%) had blood loss 
more than 500 ml. Among the patients who had C/S (n=36), one (3%) subject 
had a blood loss more than 1000ml  
 
5.3 TRANSFUSION 
 
Thirteen (13) units of whole blood were transfused; 250 units of red blood cells 
were transfused and 33 units of fresh frozen plasma units were transfused while 
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only (1) one unit of platelet was transfused. 
 
Eighteen (18.4%) patients were transfused during antepartum and intrapartum 
period and 81 (81.6%) of them were transfused during postpartum period unlike 
the study done by Parker, et al (2009) and Basu et al (2012), which reported 96% 
of the transfusion was done during postpartum period.  
 
The median pre-transfusion Hb was 6.9 g/dl which is lower than the Hb level 7.6 
g/dl reported by Basu et al (2012). The median pre-transfusion Hct and platelet 
were 0.23 and 242,000/ µl respectively. As expected the post-transfusion Hb and 
Hct improved significantly after transfusion.  
 
All the patients received Red Blood Cells (99, 100%), which was similar to the 
findings of the study done in Johannesburg (Basu, et al, 2012). Few patients 
received whole blood (3%), Fresh Frozen Plasma (11.1%) and Platelets (1%). 
Average unit of Red blood cells transfused per patient was 2.5, which is slightly 
higher than Klapholz (1990) and Basu et al (2012) (2U/ per patient). There are 
some variations in monthly uses of these products, but they are not statistically 
significant (p=0.1).  
 
All patients who were legible to receive blood and or blood products received 
their units. None of the units were rejected, which signifies good use of these 
precious products.  
 
The turn-around times for transfusion products are of concern.  As no study had 
reported this before, it is difficult to benchmark the findings of this study. 
However, the median time interval between prescription and ordering blood was 
30 min, whereas median time interval between order and receipt was 50 min and 
median time interval between receipt and administration was 60 min. The median 
time interval between prescription and administration was 160 min which is quite 
long, in an emergency situation like antepartum or post-partum haemorrhage.   
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5.4 COST OF TRANSFUSION 
 
The cost of Whole blood was R7, 433.37, Red Blood Cell R282, 192.50, Fresh 
Frozen Plasma R33, 411.37 and Platelet R6, 542.03.  The total cost of 
transfusion during one year study period was R 329,579.27. The average cost of 
transfusion per patient was R3329.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
35 
 
CHAPTER 6 
CONCLUSION AND DISCUSSION 
 
In this chapter, the results obtained from this study were assessed in relation to 
the aims and objectives of the study, so that appropriate conclusions can be 
drawn. The limitations of the study are listed. Based on the findings of the study, 
appropriate recommendations and suggestions for future research are included.  
 
6.1 CONCLUSIONS RELATED TO THE AIMS OF THE STUDY 
 
This was a cross-sectional study that looked at broad issues pertaining to the use 
of blood and blood products in the Maternity ward of the Boitumelo Regional 
Hospital, and the factors associated with these specified blood and blood 
products during one study period 
 
6.1.1 DESCRIPTION OF THE SPECIFIED BLOOD AND BLOOD 
PRODUCTS ORDERED IN THIS WARD DURING THE STUDY 
PERIOD 
 
During the one year study period, 13 units of whole blood were transfused; 250 
units of red blood cells were transfused and 33 units of fresh frozen plasma units 
were transfused while only 1 unit of platelet was transfused. 
 
6.1.2 DETERMINATION OF THE NUMBER OF PATIENTS WHO 
RECEIVED TRANSFUSION DURING THE STUDY PERIOD 
 
Ninety-nine (4.2%) among these 2304 patients delivered during this one year 
period received blood and blood products transfusion. 
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6.1.3 DETERMINATION OF THE FACTORS ASSOCIATED WITH 
UTILIZATION OF THESE PRODUCTS IN THE MATERNITY 
WARD DURING THE STUDY PERIOD 
 
Primiparity (32, 32.6%), pre-term labour (49, 49.5%), booking status (unbooked 
20, 20.4%) were found to be common among these patients. A significant 
number of them (36, 36.4%) were anaemic based on their booking Hb but only a 
few of them were diagnosed and treated for anaemia. Among the other antenatal 
diseases, Pregnancy Induced hypertension was commonest (27.3%) followed by 
HIV (15.2%).  
 
The majority of the subjects who received transfusion, (59, 59.6%) had NVD. 
Only 5% (36/776) CS patients received transfusion, which is much lower than 
other studies. The median blood loss during delivery was 400 ml.  
 
Seventeen (17.5%) patients were transfused before delivery and one (1%) was 
transfused during delivery and 81 patients (81.5%) were transfused after 
delivery. Eighteen of them (18.4%) were transfused for APH and 81 (81.6%) of 
them were transfused for PPH.  
 
6.1.4 DETERMINATION OF THE TURN-AROUND TIME OF THESE 
PRODUCTS 
 
The median time interval between prescription and administration was 160 min 
which is quite long, and are of concern.  Although the time interval between order 
and receipt (median 50 min) could be necessary for cross-match, the other two 
components (a) interval between prescription and ordering blood (median 30 
min)  and (b) time interval between receipt and administration (median 60 min) 
could easily be reduced.  
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6.1.5 DETERMINATION OF THE COST OF THESE PRODUCTS 
USED DURING THE STUDY PERIOD 
 
The total cost of transfusion during one year study period was R 329,579.27 
(Whole blood: R7, 433.37, Red Blood Cell: R282, 192.50, Fresh Frozen Plasma: 
R33, 411.37 and Platelet: R6, 542.03). The average cost of transfusion per 
patient was R3329.01. As no study had reported this before, it is difficult to 
benchmark the findings of this study. 
 
6.2 LIMITATIONS OF THE STUDY 
 
The major limitations were the following;  
• Completeness of the electronic records. Some of the records were not 
completed, where some information was missing. The researcher retrieved 
the files of the patients and entered them manually 
• Retrospective record review is a limitation in itself as no further clarity or 
follow up could be made as no primary data could be collected. In addition, 
no causal link could be established.  
 
6.3 RECOMMENDATIONS 
 
6.3.1 FOLLOW-UP 
 
This project is the first systematic study to be done at the Boitumelo Regional 
Hospital. This study identified the areas where management of patients could be 
improved such as early detection of anaemia based on booking Hb and provision 
of treatment to these patients. In addition, significantly a significant number of 
patients who were transfused delivered normally. There might be a need to have 
active management of third stage to prevent PPH.  
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The results of the study will be disseminated to the Chief Executive Officer for the 
Hospital, Chief Director for the district and Executive Manager: Clinical Health 
Services.  
 
6.3.2 FUTURE RESEARCH  
 
Based on findings of this study, the researcher would like to suggest following 
future studies: 
 
(a)  A prospective study to study all the patients who receive transfusion 
(including medical and surgical wards) at all the regional hospitals in the 
Free State Province to compare the use of blood and blood products in 
these institutions 
(b) A follow-up study to evaluate the impact of transfusion on the patients who 
receive transfusions.  
 
6.4 SUMMARY AND CONCLUSIONS  
 
This is probably the first study done at a regional hospital setting in South Africa 
which looked at broad issues pertaining to the use of blood and blood products in 
the Maternity ward of the Boitumelo Regional Hospital, and the factors 
associated with these specified blood and blood products during one study 
period. The study found 99 (4.2%) among these 2304 patients delivered during 
this one year period received blood and blood products transfusion (13 units of 
whole blood, 250 units of red blood cells,  33 units of fresh frozen plasma and  1 
unit of platelet). Primiparity, pre-term labour, booking status, was found to be 
common among these patients. A significant number of them (36, 36.4%) were 
anaemic based on their booking Hb but only a few of them were diagnosed and 
treated for anaemia. The majority of the subjects who received transfusion had 
NVD signifies the need for active management of third stage.  The median blood 
loss during delivery was 400 ml. The majority of them were transfused during 
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postpartum period for PPH. The median time interval between prescription and 
administration was 160 min which is quite long and could be improved by 
reducing the interval between prescription and ordering blood and interval 
between receipt and administration. The total cost of transfusion during one year 
study period was R 329,579.27 and the average cost of transfusion per patient 
was R3329.01. The findings of this study will be reported to the Hospital 
management for improving management of obstetrics patients. The researcher 
also proposed further study among all the patients who received transfusion at all 
the regional hospitals in the Free State Province to compare the use of blood and 
blood products in these institutions.  
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